Definitive Healthcare (NASDAQ:DH) Releases FY 2024 Earnings Guidance

Definitive Healthcare (NASDAQ:DH) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 0.320-0.340 for the period, compared to the consensus estimate of 0.370. The company issued revenue guidance of $247.0 million-$251.0 million, compared to the consensus revenue estimate of $258.3 million. Definitive Healthcare also updated its FY24 guidance to $0.32-0.34 EPS.

Definitive Healthcare Price Performance

Shares of DH stock traded down $0.23 during trading hours on Tuesday, reaching $5.74. The company’s stock had a trading volume of 3,696,056 shares, compared to its average volume of 710,079. The firm’s 50 day simple moving average is $5.55 and its 200-day simple moving average is $7.17. The company has a market capitalization of $676.92 million, a price-to-earnings ratio of -3.28, a PEG ratio of 4.36 and a beta of 1.30. Definitive Healthcare has a fifty-two week low of $4.38 and a fifty-two week high of $11.97. The company has a quick ratio of 2.30, a current ratio of 2.30 and a debt-to-equity ratio of 0.20.

Definitive Healthcare (NASDAQ:DH) last issued its earnings results on Tuesday, May 7th. The company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.04). The business had revenue of $63.48 million during the quarter, compared to analyst estimates of $64.00 million. Definitive Healthcare had a negative net margin of 78.16% and a positive return on equity of 0.51%. Sell-side analysts forecast that Definitive Healthcare will post 0.1 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Stifel Nicolaus dropped their price target on Definitive Healthcare from $11.00 to $9.50 and set a buy rating for the company in a research note on Wednesday, May 8th. Barclays dropped their price target on Definitive Healthcare from $11.00 to $7.00 and set an equal weight rating for the company in a research note on Thursday, May 9th. Needham & Company LLC reiterated a hold rating on shares of Definitive Healthcare in a research note on Wednesday, May 8th. Deutsche Bank Aktiengesellschaft dropped their price target on Definitive Healthcare from $10.00 to $7.00 and set a hold rating for the company in a research note on Thursday, May 9th. Finally, Canaccord Genuity Group dropped their price target on Definitive Healthcare from $10.00 to $8.00 and set a hold rating for the company in a research note on Wednesday, May 8th. Eight investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of Hold and a consensus price target of $9.56.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.